Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Neutral

Analyst Rating

Strong Buy

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Buy

Insider Trading

Neutral

Wall Street Data Solutions Rating

Buy

A

AstraZeneca PLC (AZN)

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/18/1993

Market Cap

262,121,342,400

Shares Outstanding

1,550,160,000

Weighted SO

3,100,325,252

Total Employees

N/A

Upcoming Earnings

07/25/2024

Similar Tickers

NVS --.--%

GSK --.--%

RHHBY --.--%

BMY --.--%

SNY --.--%

MRK --.--%

GILD --.--%

JNJ --.--%

ABBV --.--%

Beta

0.1480

Last Div

1.4900

Range

60.47-85.3

Chg

-0.3600

Avg Vol

4159738

Mkt Cap

262121342400

Exch

NASDAQ

Country

GB

Phone

44 20 3749 5000

DCF Diff

-23.3378

DCF

107.8278

Div Yield

0.0174

P/S

5.3349

EV Multiple

19.4384

P/FV

6.6328

Div Yield %

1.7447

P/E

40.6947

PEG

2.2748

Payout

0.6929

Current Ratio

0.8889

Quick Ratio

0.6905

Cash Ratio

0.2421

DSO

93.7665

DIO

193.4763

Op Cycle

287.2428

DPO

698.6245

CCC

-411.3817

Gross Margin

0.7824

Op Margin

0.1887

Pretax Margin

0.1580

Net Margin

0.1311

Eff Tax Rate

0.1675

ROA

0.0617

ROE

0.1680

ROCE

0.1224

NI/EBT

0.8294

EBT/EBIT

0.8374

EBIT/Rev

0.1887

Debt Ratio

0.3123

D/E

0.8247

LT Debt/Cap

0.4079

Total Debt/Cap

0.4520

Int Coverage

5.5996

CF/Debt

0.3459

Equity Multi

2.6407

Rec Turnover

3.8926

Pay Turnover

0.5225

Inv Turnover

1.8865

FA Turnover

4.5355

Asset Turnover

0.4709

OCF/Share

3.6358

FCF/Share

2.3139

Cash/Share

2.2826

OCF/Sales

0.2294

FCF/OCF

0.6364

CF Coverage

0.3459

ST Coverage

2.1032

CapEx Coverage

2.7504

Div&CapEx Cov

1.3167

P/BV

6.6328

P/B

6.6328

P/S

5.3349

P/E

40.6947

P/FCF

36.5428

P/OCF

23.2521

P/CF

23.2521

PEG

2.2748

P/S

5.3349

EV Multiple

19.4384

P/FV

6.6328

DPS

1.4750

Latest Headlines (EST)

GlobeNewswire Inc. Mar 29, 16:32 SFJ Pharmaceuticals & SERB Pharmaceuticals Present Positive Final Results from Pivotal Ph 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Surgery or Experiencing Major Bleeding GlobeNewswire Inc. Mar 10, 00:30 Global Prostate Cancer Market to Reach USD 29.2 Billion by 2035, Driven by Aging Population and Awareness | Future Market Insights, Inc. GlobeNewswire Inc. Feb 15, 22:50 AZN IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important February 21 Deadline in Securities Class Action First Filed by the Firm – AZN The Motley Fool Feb 15, 13:45 2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025 GlobeNewswire Inc. Feb 09, 16:14 ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important February 21 Deadline in Securities Class Action First Filed by the Firm – AZN GlobeNewswire Inc. Jan 30, 23:52 ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN GlobeNewswire Inc. Jan 30, 02:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AstraZeneca, IIPR, Block, and Crocs and Encourages Investors to Contact the Firm GlobeNewswire Inc. Jan 22, 02:04 ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN GlobeNewswire Inc. Jan 18, 14:21 ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN GlobeNewswire Inc. Jan 13, 23:55 AstraZeneca PLC Investors: Please contact the Portnoy Law Firm to recover your losses. February 21, 2025 Deadline to file Lead Plaintiff Motion GlobeNewswire Inc. Jan 13, 03:17 ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN GlobeNewswire Inc. Jan 12, 21:00 AZN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit GlobeNewswire Inc. Jan 09, 23:30 ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN GlobeNewswire Inc. Jan 09, 03:46 ASTRAZENECA SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against AstraZeneca PLC - AZN GlobeNewswire Inc. Jan 08, 03:49 ASTRAZENECA SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against AstraZeneca PLC - AZN GlobeNewswire Inc. Jan 04, 00:57 ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN GlobeNewswire Inc. Jan 03, 23:59 AstraZeneca PLC Investors: Please contact the Portnoy Law Firm to recover your losses. February 21, 2025 Deadline to file Lead Plaintiff Motion GlobeNewswire Inc. Jan 01, 15:07 AstraZeneca (AZN) Reels from China Investigation and Investor Suit – Hagens Berman GlobeNewswire Inc. Dec 27, 19:16 ROSEN, A TOP-RANKED LAW FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN GlobeNewswire Inc. Dec 25, 01:33 ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
0.98 02/22/2024 02/08/2024 02/23/2024 03/25/2024
0.46 08/10/2023 07/28/2023 08/11/2023 09/11/2023
0.96 02/23/2023 02/09/2023 02/24/2023 03/27/2023
0.46 08/11/2022 08/01/2022 08/12/2022 09/12/2022
0.96 02/24/2022 02/10/2022 02/25/2022 03/28/2022
0.44 08/12/2021 07/30/2021 08/13/2021 09/13/2021
0.95 02/25/2021 02/12/2021 02/26/2021 03/29/2021
0.44 08/13/2020 07/30/2020 08/14/2020 09/14/2020
0.95 02/27/2020 02/18/2020 02/28/2020 03/30/2020
0.45 08/08/2019 07/29/2019 08/09/2019 09/09/2019
0.95 02/28/2019 02/15/2019 03/01/2019 03/27/2019
0.45 08/09/2018 07/26/2018 08/10/2018 09/10/2018
0.95 02/15/2018 02/02/2018 02/16/2018 03/19/2018
0.45 08/09/2017 07/28/2017 08/11/2017 09/11/2017
0.95 02/15/2017 02/03/2017 02/17/2017 03/20/2017
0.45 08/10/2016 07/29/2016 08/12/2016 09/12/2016
0.95 02/17/2016 02/05/2016 02/19/2016 03/21/2016
0.45 08/12/2015 07/30/2015 11/30/-0001 09/14/2015
1.90 02/18/2015 02/10/2015 02/20/2015 03/23/2015
0.90 08/13/2014 07/31/2014 08/15/2014 09/15/2014
1.90 02/19/2014 02/07/2014 02/21/2014 03/24/2014
0.90 08/14/2013 08/01/2013 08/16/2013 09/16/2013
1.90 02/13/2013 01/31/2013 02/15/2013 03/18/2013
0.90 08/08/2012 07/26/2012 11/30/-0001 09/10/2012
1.95 02/15/2012 02/02/2012 11/30/-0001 03/19/2012
0.85 08/04/2011 07/29/2011 11/30/-0001 09/12/2011
1.85 02/02/2011 01/27/2011 11/30/-0001 03/14/2011
0.70 08/04/2010 07/29/2010 11/30/-0001 09/13/2010
1.71 02/03/2010 01/28/2010 11/30/-0001 03/15/2010
0.59 08/05/2009 07/30/2009 11/30/-0001 09/14/2009
1.50 02/04/2009 11/30/-0001 11/30/-0001 11/30/-0001
0.55 08/06/2008 11/30/-0001 11/30/-0001 11/30/-0001
1.35 02/07/2008 11/30/-0001 11/30/-0001 11/30/-0001
0.52 08/08/2007 11/30/-0001 11/30/-0001 11/30/-0001
1.23 02/07/2007 11/30/-0001 11/30/-0001 11/30/-0001
0.49 08/09/2006 11/30/-0001 11/30/-0001 11/30/-0001
0.92 02/08/2006 11/30/-0001 11/30/-0001 11/30/-0001
0.38 08/10/2005 11/30/-0001 11/30/-0001 11/30/-0001
0.64 02/09/2005 11/30/-0001 11/30/-0001 11/30/-0001
0.30 08/11/2004 11/30/-0001 11/30/-0001 11/30/-0001
0.54 02/18/2004 11/30/-0001 11/30/-0001 11/30/-0001
0.26 08/20/2003 11/30/-0001 11/30/-0001 11/30/-0001
0.52 02/19/2003 11/30/-0001 11/30/-0001 11/30/-0001
0.26 08/21/2002 11/30/-0001 11/30/-0001 11/30/-0001
0.52 02/20/2002 11/30/-0001 11/30/-0001 11/30/-0001
0.26 08/22/2001 11/30/-0001 11/30/-0001 11/30/-0001
0.52 02/21/2001 11/30/-0001 11/30/-0001 11/30/-0001
1.07 11/14/2000 11/30/-0001 11/30/-0001 11/30/-0001
0.26 09/06/2000 11/30/-0001 11/30/-0001 11/30/-0001
0.52 03/08/2000 11/30/-0001 11/30/-0001 11/30/-0001
0.26 09/08/1999 11/30/-0001 11/30/-0001 11/30/-0001
0.35 04/07/1999 11/30/-0001 11/30/-0001 11/30/-0001
0.28 09/16/1998 11/30/-0001 11/30/-0001 11/30/-0001
1.54 03/18/1998 11/30/-0001 11/30/-0001 11/30/-0001
0.80 09/17/1997 11/30/-0001 11/30/-0001 11/30/-0001
1.34 03/19/1997 11/30/-0001 11/30/-0001 11/30/-0001
0.72 09/20/1996 11/30/-0001 11/30/-0001 11/30/-0001
0.76 03/22/1996 11/30/-0001 11/30/-0001 11/30/-0001
0.67 09/22/1995 11/30/-0001 11/30/-0001 11/30/-0001
1.05 03/24/1995 11/30/-0001 11/30/-0001 11/30/-0001
0.62 09/23/1994 11/30/-0001 11/30/-0001 11/30/-0001
0.94 03/18/1994 11/30/-0001 11/30/-0001 11/30/-0001
0.58 09/24/1993 11/30/-0001 11/30/-0001 11/30/-0001